Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer

被引：55

作者：

Bouchahda, M. ^{[1
]}

Macarulla, T. ^{[2
]}

Spano, J. P. ^{[3
]}

Bachet, J. B. ^{[4
]}

Lledo, G. ^{[5
]}

Andre, T. ^{[6
]}

Landi, B. ^{[7
]}

Tabernero, J. ^{[2
]}

Karaboue, A.

Domont, J. ^{[3
]}

Levi, F.

Rougier, P. ^{[4
]}

机构：

[1] Hop Paul Brousse, Med Oncol Serv, F-94800 Villejuif, France

[2] Valle Hebron Univ Hosp, Barcelona, Spain

[3] Hop La Pitie Salpetriere, Paris, France

[4] Hop Ambroise Pare, Paris, France

[5] Clin St Jean, Lyon, France

[6] Hop Tenon, F-75970 Paris, France

[7] Hop Europeen Georges Pompidou, Paris, France

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2008年 / 67卷 / 03期

关键词：

cetuximab; chemotherapy; colorectal cancer; elderly;

D O I：

10.1016/j.critrevonc.2008.02.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Few data are available from clinical trials for elderly patients receiving cetuximab. Patients and methods: The clinical data of consecutive patients aged >= 70 years given cetuximab for metastatic CRC were retrospectively captured from hospital pharmacy registries in seven centers. Results: Fifty-six patients received cetuximab with irinotecan. Median age was 76 years (70-84), 86% of patients were pretreated with fluoropyrimidines, irinotecan and oxaliplatin and 69.6% had documented resistance to irinotecan. Objective response rate was 21% (95% CI: 11-32%). The median progression-free survival was 4.4 months (95% Cl: 3.0-5.7 months) and the median overall survival was 16.0 months (95% CI: 13.5-18.5 months). Skin rash occurred in 75% of the patients (11% grade 3) and diarrhea in 80% (20% grades 3-4). Conclusion: Tolerability of cetuximab was acceptable in elderly patients with pretreated metastatic CRC. Efficacy appeared similar to that observed in younger patients. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

引用

页码：255 / 262

页数：8

共 50 条

[41] Cetuximab in the treatment of metastatic colorectal cancer [J].

Moosmann, Nicolas ;

Heinemann, Volker .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (02) :243-256

[42] Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer [J].

Jehn, C. F. ;

Boening, L. ;

Kroening, H. ;

Pezzutto, A. ;

Lueftner, D. .

EUROPEAN JOURNAL OF CANCER, 2014, 50 (07) :1269-1275

[43] Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution [J].

Sonoda, Hiromichi ;

Mekata, Eiji ;

Shimizu, Tomoharu ;

Endo, Yoshihiro ;

Tani, Tohru .

ONCOLOGY LETTERS, 2013, 5 (04) :1331-1334

[44] Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer [J].

Gerardo Rosati ;

Raffaele Addeo ;

Giuseppe Aprile ;

Antonio Avallone ;

Domenico Bilancia ;

Silvia Brugnatelli ;

Gabriella Buccafusca ;

Chiara Carlomagno ;

Stefano Cordio ;

Sara Delfanti ;

Emanuela Dell’Aquila ;

Maurizio Di Bisceglie ;

Samantha Di Donato ;

Antonio Di Stasi ;

Domenico Germano ;

Francesco Giuliani ;

Cristina Granetto ;

Tiziana Pia Latiano ;

Silvana Leo ;

Paolo Tralongo ;

Maria Elena Stroppolo ;

Filippo Venturini ;

Salvatore Bianco .

Cancer Chemotherapy and Pharmacology, 2019, 84 :1089-1096

[45] Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients [J].

Pfeiffer, Per ;

Qvortrup, Camilla ;

Bjerregaard, Jon K. .

ONCOTARGETS AND THERAPY, 2009, 2 :17-27

[46] Retrospective study of cetuximab in combination with chemotherapy for patients with colorectal cancer [J].

Zhihao Lu Xiaotian Zhang Lin Shen Xiaodong Zhang Jie Li Zhongtao Zhang Department of GI Oncology Peking University School of Oncology Beijing Cancer Hospital Institute Beijing China Department of General Surgery Beijing Youyi Hospital Beijing China .

Chinese-German Journal of Clinical Oncology, 2008, (07) :400-403

[47] The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients [J].

Ozcelik, M. ;

Odabas, H. ;

Ercelep, O. ;

Yuksel, S. ;

Mert, A. G. ;

Aydin, D. ;

Surmeli, H. ;

Isik, D. ;

Isik, S. ;

Oyman, A. ;

Ustaalioglu, B. B. Oven ;

Aliustaoglu, M. ;

Gumus, M. .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (06) :617-624

[48] Efficacy and Safety of Bevacizumab in Chinese Patients with Metastatic Colorectal Cancer [J].

Zhu, Li-Ming ;

Zhao, Ya-Zhen ;

Ju, Hai-Xing ;

Liu, Lu-Ying ;

Chen, Lei ;

Liu, Bi-Xia ;

Xu, Qi ;

Luo, Cong ;

Ying, Jie-Er ;

Yang, Yun-Shan ;

Zhong, Hai-Jun .

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (16) :6559-6564

[49] The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy [J].

Giampieri, Riccardo ;

Restivo, Angelo ;

Pusceddu, Valeria ;

Del Prete, Michela ;

Maccaroni, Elena ;

Bittoni, Alessandro ;

Faloppi, Luca ;

Andrikou, Kalliopi ;

Bianconi, Maristella ;

Cabras, Francesco ;

Berardi, Rossana ;

Zorcolo, Luigi ;

Scintu, Francesco ;

Cascinu, Stefano ;

Scartozzi, Mario .

CLINICAL COLORECTAL CANCER, 2017, 16 (01) :38-43

[50] The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer [J].

Diaz-Serrano, Asuncion ;

Riesco-Martinez, Maria C. ;

Garcia-Carbonero, Rocio .

EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (06) :585-595

← 1 2 3 4 5 →